Literature DB >> 8286418

Specific 3' sequences flanking a minimal apolipoprotein B (apoB) mRNA editing 'cassette' are critical for efficient editing in vitro.

J W Backus1, H C Smith.   

Abstract

Apolipoprotein B (apoB) mRNA in mammalian intestine undergoes direct conversion of cytidine to uridine at nucleotide 6666, generating a UAA stop codon which defines the carboxyl-terminus of apoB48. We have identified three distinct sequence elements which are required for efficient apoB RNA editing in vitro and have defined a 20 nucleotide 'editing cassette' which will support efficient editing in the context of a variety of AT-rich apoB mRNA backgrounds. An important question remaining to be addressed is whether this cassette can support editing in a GC-rich background characteristic of other mRNAs. We demonstrate that the context into which the editing cassette is inserted may determine the efficiency of editing site utilization. When an editing cassette is placed in the context of human albumin mRNA sequence, editing is reduced 6-fold relative to a construct of similar length in which the cassette is surrounded by apoB mRNA sequence. Chimeric RNA substrates may be efficiently edited, however, when albumin sequence resides only 5' of the editing cassette. The data suggest that the proximal of an AT-rich, apoB-like, mRNA sequence is only required 3' of the editing cassette. These results should prove useful in evaluating the potential for editing on mRNAs where similar cassettes can be found.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8286418

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

Review 1.  Gene regulation by mRNA editing.

Authors:  J Ashkenas
Journal:  Am J Hum Genet       Date:  1997-02       Impact factor: 11.025

2.  Multiple protein domains determine the cell type-specific nuclear distribution of the catalytic subunit required for apolipoprotein B mRNA editing.

Authors:  Y Yang; Y Yang; H C Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

3.  Metabolic regulation of APOBEC-1 complementation factor trafficking in mouse models of obesity and its positive correlation with the expression of ApoB protein in hepatocytes.

Authors:  Chad A Galloway; John Ashton; Janet D Sparks; Robert A Mooney; Harold C Smith
Journal:  Biochim Biophys Acta       Date:  2010-06-09

4.  Guide RNA-mRNA chimeras, which are potential RNA editing intermediates, are formed by endonuclease and RNA ligase in a trypanosome mitochondrial extract.

Authors:  L N Rusché; K J Piller; B Sollner-Webb
Journal:  Mol Cell Biol       Date:  1995-06       Impact factor: 4.272

5.  Identification of the yeast cytidine deaminase CDD1 as an orphan C-->U RNA editase.

Authors:  G S Dance; P Beemiller; Y Yang; D V Mater; I S Mian; H C Smith
Journal:  Nucleic Acids Res       Date:  2001-04-15       Impact factor: 16.971

6.  Apolipoprotein B RNA sequence 3' of the mooring sequence and cellular sources of auxiliary factors determine the location and extent of promiscuous editing.

Authors:  M P Sowden; M J Eagleton; H C Smith
Journal:  Nucleic Acids Res       Date:  1998-04-01       Impact factor: 16.971

7.  Commitment of apolipoprotein B RNA to the splicing pathway regulates cytidine-to-uridine editing-site utilization.

Authors:  M P Sowden; H C Smith
Journal:  Biochem J       Date:  2001-11-01       Impact factor: 3.857

8.  The neurofibromatosis type I messenger RNA undergoes base-modification RNA editing.

Authors:  G R Skuse; A J Cappione; M Sowden; L J Metheny; H C Smith
Journal:  Nucleic Acids Res       Date:  1996-02-01       Impact factor: 16.971

9.  A sequence-specific RNA-binding protein complements apobec-1 To edit apolipoprotein B mRNA.

Authors:  A Mehta; D M Driscoll
Journal:  Mol Cell Biol       Date:  1998-08       Impact factor: 4.272

Review 10.  Modeling the Embrace of a Mutator: APOBEC Selection of Nucleic Acid Ligands.

Authors:  Jason D Salter; Harold C Smith
Journal:  Trends Biochem Sci       Date:  2018-05-23       Impact factor: 13.807

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.